Half a world away from Washington, Asia’s corporate titans are coming to grips with the new, or perhaps all too familiar, ...

In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

When Genentech licensed experimental drug vixarelimab from Kiniksa Pharmaceuticals KNSA-1.57%decrease; red down pointing triangle, its scientists thought they had a future lung medicine in their ...

"Our new identity combines our established leadership with our vision for future growth, as we embrace a broader pharmaceuticals market." Over the years, the Company has remained committed to ...

At the heart of this evolution lies the growing prominence of biologics contract manufacturing, a strategic partnership that is reshaping the way pharmaceutical companies approach their production ...

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...